Hypervascular Hepatocellular Carcinomas Showing Hyperintensity on Hepatobiliary Phase of Gadoxetic Acid-enhanced Magnetic Resonance Imaging: a Possible Subtype with Mature Hepatocyte Nature

Overview

Journal Jpn J Radiol

Publisher Springer

Specialty Radiology

Date 2013 Jun 18

PMID 23771695

Citations 11

Authors

Norihide Yoneda

Osamu Matsui

Azusa Kitao

Ryuichi Kita

Kazuto Kozaka

Wataru Koda

Satoshi Kobayashi

Toshifumi Gabata

Hiroko Ikeda

Yasuni Nakanuma

Affiliations

Soon will be listed here.

Abstract

Purpose: We evaluated molecular features of hypervascular hepatocellular carcinoma (HCC) that shows iso- or hyperintensity (hyperintense HCC) in the hepatobiliary phase (HB phase) of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI).

Materials And Methods: We investigated 89 surgically resected cases. Patients were divided into two groups according to the signal intensity in the HB phase of EOB-MRI: hyperintense HCCs (n = 18) and hypointense HCCs (n = 71). We performed immunohistochemical staining for uptake transporter of gadoxetic acid: organic anion transporter polypeptides (OATP8); tumor markers: alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II); hepatic stem cell markers: epithelial cell adhesion molecule (EpCAM), cytokeratin 19 (CK19), and neural cell adhesion molecule (NCAM); biliary marker: CK7; hepatocyte marker: hepatocyte paraffin 1 (HepPar1); markers of HCC differentiation: glypican-3; signaling: beta-catenin, and the respective grade was semiquantitatively determined.

Results: Histopathologically, hyperintense HCCs showed significantly weaker expression of AFP (p < 0.05), PIVKA-II (p < 0.01), EpCAM (p < 0.005), glypican-3 (p < 0.005) relative to the hypointense HCCs, whereas OATP8 (p < 0.0001), HepPar1 (p < 0.05), and beta-catenin (p < 0.001) were overexpressed in hyperintense HCCs compared with hypointense HCCs.

Conclusion: Hyperintense HCC expressed OATP8 and showed a feature of mature hepatocytes with a weak expression of stem cell characteristics immunohistochemically. In addition, this type of HCC demonstrated a weaker expression of the poorer prognosis markers including, AFP, PIVKA-II, EpCAM, CK19, and glypican-3.

Citing Articles

Radiologic features of hepatocellular carcinoma related to prognosis.

Hwang S, Rhee H J Liver Cancer. 2023; 23(1):143-156.

PMID: 37384030 PMC: 10202237. DOI: 10.17998/jlc.2023.02.16.

Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoxetic Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.

Minamiguchi K, Nishiofuku H, Saito N, Sato T, Taiji R, Matsumoto T Cancers (Basel). 2023; 15(4).

PMID: 36831582 PMC: 9954181. DOI: 10.3390/cancers15041238.

Current Imaging Diagnosis of Hepatocellular Carcinoma.

Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P Cancers (Basel). 2022; 14(16).

PMID: 36010991 PMC: 9406360. DOI: 10.3390/cancers14163997.

An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation.

Kovac J, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore R Radiol Oncol. 2021; 55(2):130-143.

PMID: 33544992 PMC: 8042819. DOI: 10.2478/raon-2021-0004.

Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma.

Kovac J, Milovanovic T, Dugalic V, Dumic I World J Gastroenterol. 2020; 26(17):2012-2029.

PMID: 32536771 PMC: 7267693. DOI: 10.3748/wjg.v26.i17.2012.

References

Reimer P, Schneider G, Schima W . Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004; 14(4):559-78. DOI: 10.1007/s00330-004-2236-1. View

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H . EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136(3):1012-24. PMC: 2828822. DOI: 10.1053/j.gastro.2008.12.004. View

Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K . Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009; 44(7):793-8. DOI: 10.1007/s00535-009-0056-4. View

Bluemke D, Sahani D, Amendola M, Balzer T, Breuer J, Brown J . Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005; 237(1):89-98. DOI: 10.1148/radiol.2371031842. View

Wu P, Fang J, Lau V, Lai C, Lo C, Lau J . Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996; 149(4):1167-75. PMC: 1865193. View

Reimer P, Rummeny E, Shamsi K, Balzer T, Daldrup H, Tombach B . Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199(1):177-83. DOI: 10.1148/radiology.199.1.8633143. View

Thorgeirsson S, Grisham J . Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002; 31(4):339-46. DOI: 10.1038/ng0802-339. View

Vander Borght S, Libbrecht L, Blokzijl H, Faber K, Moshage H, Aerts R . Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol. 2005; 207(4):471-82. DOI: 10.1002/path.1852. View

Vogl T, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T . Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996; 200(1):59-67. DOI: 10.1148/radiology.200.1.8657946. View

10.

Zhou H, Rogler L, Teperman L, Morgan G, Rogler C . Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver. Hepatology. 2007; 45(3):716-24. DOI: 10.1002/hep.21557. View

11.

Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-50. DOI: 10.1038/nature03319. View

12.

Yamashita T, Forgues M, Wang W, Kim J, Ye Q, Jia H . EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5):1451-61. DOI: 10.1158/0008-5472.CAN-07-6013. View

13.

Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M . Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2002; 17(7):772-8. DOI: 10.1046/j.1440-1746.2002.02806.x. View

14.

Di Bisceglie A . Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S104-7. DOI: 10.1053/j.gastro.2004.09.022. View

15.

Dan Y, Riehle K, Lazaro C, Teoh N, Haque J, Campbell J . Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A. 2006; 103(26):9912-7. PMC: 1502553. DOI: 10.1073/pnas.0603824103. View

16.

Nhieu J, Renard C, Wei Y, Cherqui D, Zafrani E, Buendia M . Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999; 155(3):703-10. PMC: 1866892. DOI: 10.1016/s0002-9440(10)65168-1. View

17.

Yamashita T, Budhu A, Forgues M, Wang X . Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007; 67(22):10831-9. DOI: 10.1158/0008-5472.CAN-07-0908. View

18.

Heppner G . Tumor heterogeneity. Cancer Res. 1984; 44(6):2259-65. View

19.

Rebouissou S, Couchy G, Libbrecht L, Balabaud C, Imbeaud S, Auffray C . The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol. 2008; 49(1):61-71. DOI: 10.1016/j.jhep.2008.03.013. View

20.

Lee J, Heo J, Libbrecht L, Chu I, Kaposi-Novak P, Calvisi D . A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410-6. DOI: 10.1038/nm1377. View